#Sweden #London #Hansa Biopharma #imlifidase #ESOT Congress

Hansa Biopharma's Promising Outcomes for Imlifidase in Kidney Transplants

At the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), Hansa Biopharma AB, a leading biopharmaceutical company based in Sweden, shared encouraging findings from a five-year follow-up study on imlifidase, an innovative treatment for kidney transplant patients. The presentation, led by Dr. Massimo Mangiola of the NYU Langone Transplant Institute, highlights notable long-term results from the extended analysis of the 17-HMedIdeS-14 study, featuring patients who underwent desensitization prior to kidney transplant surgery.

The analysis showcased that patients treated with imlifidase and who received kidney transplants maintain impressive outcomes five years post-operation. Specifically, the study reported a remarkable 90% survival rate among transplant recipients after five years, despite three deaths occurring within the first year following the procedure. Additionally, the graft survival rate, which measures whether the transplanted kidney continues to function, was reported at 82%, aligning with the three-year results previously noted. Moreover, kidney function, measured through estimated glomerular filtration rate (eGFR), averaged 50 mL/min/m² among patients, a favorable result considering that typical eGFR values for transplant recipients often decline over time.

Dr. Kaufmann, Chief R&D Officer at Hansa Biopharma, expressed satisfaction with these findings, indicating that this extended analysis significantly boosts the clinical community's confidence in imlifidase. He emphasized that the study is groundbreaking, as it demonstrates for the first time that transplantation from HLA-incompatible donors through desensitization with imlifidase is a feasible and beneficial option for highly sensitized patients—those with pre-existing antibodies against donor organs, often hindering transplant opportunities.

The 17-HMedIdeS-14 study is part of a broader clinical program focusing on the application of imlifidase, which includes various other trials aimed at enhancing our understanding of its efficacy and safety. This latest analysis marks an extension of earlier studies and reinforces the substantial advantages that imlifidase provides for patients who would otherwise face extended wait times for kidney transplants due to their sensitized status.

Hansa Biopharma’s imlifidase operates by cleaving certain antibodies that pose challenges during the transplantation process, thus paving the way for successful surgeries in patients with complex immunological profiles. The data signifies a key turning point for treating highly sensibilized patients, who constitute roughly 10-15% of kidney transplant waiting lists in the U.S. and Europe.

Given the substantial health burden posed by End-Stage Renal Disease (ESRD) affecting millions globally, Hansa Biopharma’s ongoing efforts in refining and promoting imlifidase offer hope to countless patients needing a kidney transplant. With positive findings at ESOT 2025, the company continues to strive towards making a meaningful impact in the field of organ transplantation, thereby changing lives through cutting-edge medical innovations.

As Hansa Biopharma charts its course forward, the findings presented at the congress underscore the promising trajectory of imlifidase as a viable option within the transplantation landscape—a breakthrough for individuals who face severe immunological hurdles that could otherwise exclude them from receiving lifesaving treatment.